Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 9/2010

01-09-2010 | Hepatobiliary Tumors

Prospective Study of Outcomes after Percutaneous Biliary Drainage for Malignant Biliary Obstruction

Authors: P. C. Robson, BA, BSN, RN, N. Heffernan, BSN, RN, M. Gonen, PhD, R. Thornton, MD, L. A. Brody, MD, R. Holmes, BS, K. T. Brown, MD, A. M. Covey, MD, D. Fleischer, NP, G. I. Getrajdman, MD, W. Jarnagin, MD, C. Sofocleous, MD, L. Blumgart, MD, M. D’Angelica, MD

Published in: Annals of Surgical Oncology | Issue 9/2010

Login to get access

Abstract

Background

Percutaneous biliary drainage (PBD) is used to relieve malignant bile duct obstruction (MBO) when endoscopic drainage is not feasible. Little is known about the effects of PBD on the quality of life (QoL) in patients with MBO. The aim of this study was to evaluate changes in QoL and pruritus after PBD and to explore the variables that impact these changes.

Materials and Methods

Eligible patients reported their QoL and pruritus before and after PBD using the Functional Assessment of Cancer Therapy–Hepatobiliary instrument (FACT-HS) and the Visual Analog Scale for Pruritus (VASP). Instruments were completed preprocedure and at 1 and 4 weeks following PBD.

Results

A total of 109 (60 male/49 female) patients enrolled; 102 (94%) had unresectable disease. PBD was technically successful (hepatic ducts cannulated at the conclusion of procedure) in all patients. There were 2 procedure-related deaths. All-cause mortality was 10% (N = 11) at 4 weeks and 28% (N = 31) at 8 weeks post-PBD with a median survival of 4.74 months. The mean FACT-HS scores declined significantly (P < .01) over time (101.3, 94.8, 94.7 at baseline, 1 week, 4 weeks, respectively). The VASP scores showed significant improvement at 1 week with continued improvement at 4 weeks (P < .01).

Conclusions

PBD improves pruritus but not QoL in patients with MBO and advanced malignancy. There is high early mortality in this population.
Literature
1.
Blumgart LH, Belghiti J, Jarnigan WR, DeMatteo RP, Chapman WC, Butler MW, editors. Surgery of the liver, biliary tract, and pancreas. 4th ed. Philadelphia: Saunders Elsevier; 2007.
2.
Ferrucci JT, Jr., Mueller PR, Harbin WP. Percutaneous transhepatic biliary drainage: technique, results, and applications. Radiology. 1980;135:1–13.PubMed
3.
Singhal D, van Gulik TM, Gouma DJ. Palliative management of hilar cholangiocarcinoma. Surg Oncol. 2005;14:59–74.CrossRefPubMed
4.
van Delden OM, Lameris JS. Percutaneous drainage and stenting for palliation of malignant bile duct obstruction. Eur Radiol. 2008;18:448–56.CrossRefPubMed
5.
Jarnagin WR, Burke E, Powers C, Fong Y, Blumgart LH. Intrahepatic biliary enteric bypass provides effective palliation in selected patients with malignant obstruction at the hepatic duct confluence. Am J Surg. 1998;175:453–60.CrossRefPubMed
6.
Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002;51(Suppl 6):VI1–9.
7.
Liu CL, Lo CM, Lai EC, Fan ST. Endoscopic retrograde cholangiopancreatography and endoscopic endoprosthesis insertion in patients with Klatskin tumors. Arch Surg. 1998;133:293–6.CrossRefPubMed
8.
Saluja SS, Gulati M, Garg PK, Pal H, Pal S, Sahni P, et al. Endoscopic or percutaneous biliary drainage for gallbladder cancer: a randomized trial and quality of life assessment. Clin Gastroenterol Hepatol. 2008;6:944–50 e3.
9.
Pinol V, Castells A, Bordas JM, Real MI, Llach J, Montana X, et al. Percutaneous self-expanding metal stents versus endoscopic polyethylene endoprostheses for treating malignant biliary obstruction: randomized clinical trial. Radiology. 2002;225:27–34.CrossRefPubMed
10.
Heffernan N, Cella D, Webster K, Odom L, Martone M, Passik S, et al. Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol. 2002;20:2229–39.
11.
Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997;15:974–86.PubMed
12.
Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995;12:199–220.CrossRefPubMed
13.
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–9.PubMed
14.
Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50:920–8.CrossRefPubMed
15.
List MA, D’Antonio LL, Cella DF, Siston A, Mumby P, Haraf D, et al. The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale. A study of utility and validity. Cancer. 1996;77:2294–301.CrossRefPubMed
16.
Ward WL, Hahn EA, Mo F, Hernandez L, Tulsky DS, Cella D. Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. Qual Life Res. 1999;8:181–95.CrossRefPubMed
17.
Steel J, Baum A, Carr B. Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere). Psychooncology. 2004;13:73–9.CrossRefPubMed
18.
19.
Yosipovitch G, Goon AT, Wee J, Chan YH, Zucker I, Goh CL. Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus. Int J Dermatol. 2002;41:212–6.CrossRefPubMed
20.
Yosipovitch G, Zucker I, Boner G, Gafter U, Shapira Y, David M. A questionnaire for the assessment of pruritus: validation in uremic patients. Acta Derm Venereol. 2001;81:108–11.CrossRefPubMed
21.
Nieveen van Dijkum EJ, Kuhlmann KF, Terwee CB, Obertop H, de Haes JC, Gouma DJ. Quality of life after curative or palliative surgical treatment of pancreatic and periampullary carcinoma. Br J Surg. 2005;92:471–7.CrossRefPubMed
22.
Blazeby JM, Nicklin J, Brookes ST, Winstone K, Alderson D. Feasibility of quality of life assessment in patients with upper gastrointestinal tract cancer. Br J Cancer. 4 2003;89:497–501.
23.
Covey AM, Brown KT. Palliative percutaneous drainage in malignant biliary obstruction. Part 1: indications and preprocedure evaluation. J Support Oncol. 2006;4:269–73.PubMed
24.
Kuvshinoff BW, Armstrong JG, Fong Y, Schupak K, Getradjman G, Heffernan N, et al. Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. Br J Surg. 1995;82:1522–5.CrossRefPubMed
25.
Abraham NS, Barkun JS, Barkun AN. Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life. Gastrointest Endosc. 2002;56:835–41.CrossRefPubMed
26.
Sun V, Ferrell B, Juarez G, Wagman LD, Yen Y, Chung V. Symptom concerns and quality of life in hepatobiliary cancers. Oncol Nurs Forum. 2008;35:E45–52.CrossRefPubMed
27.
Kaskarelis IS, Papadaki MG, Papageorgiou GN, Limniati MD, Malliaraki NE, Piperopoulos PN. Long-term follow-up in patients with malignant biliary obstruction after percutaneous placement of uncovered wallstent endoprostheses. Acta Radiol. 1999;40:528–33.CrossRefPubMed
28.
McPherson GA, Benjamin IS, Habib NA, Bowley NB, Blumgart LH. Percutaneous transhepatic drainage in obstructive jaundice: advantages and problems. Br J Surg. 1982;69:261–4.CrossRefPubMed
Metadata
Title
Prospective Study of Outcomes after Percutaneous Biliary Drainage for Malignant Biliary Obstruction
Authors
P. C. Robson, BA, BSN, RN
N. Heffernan, BSN, RN
M. Gonen, PhD
R. Thornton, MD
L. A. Brody, MD
R. Holmes, BS
K. T. Brown, MD
A. M. Covey, MD
D. Fleischer, NP
G. I. Getrajdman, MD
W. Jarnagin, MD
C. Sofocleous, MD
L. Blumgart, MD
M. D’Angelica, MD
Publication date
01-09-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 9/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1045-9

Other articles of this Issue 9/2010

Annals of Surgical Oncology 9/2010 Go to the issue

Translational Research and Biomarkers

Prognostic Role of Estrogen Receptor α and Estrogen Receptor β in Gastric Cancer

Gastrointestinal Oncology

Peritoneal Carcinomatosis from Gastric Cancer: A Multi-Institutional Study of 159 Patients Treated by Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy

Pancreatic Tumors

Prognostic Impact of Perioperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic Cancer

Healthcare Policy and Outcomes

Body Mass Index and Major Cancer Surgery Outcomes: Lack of Association or Need for Alternative Measurements of Obesity?

Head and Neck Oncology

Sentinel Node Biopsy in Head and Neck Squamous Cell Cancer: 5-Year Follow-Up of a European Multicenter Trial

Breast Oncology

The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy